Hexal Australia

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c29061) has announced the addition of World Generic Markets Report 2006 to their offering.

The updated, expanded and enriched 4th edition. A wealth of market, company and product intelligence on this dynamically-changing industry sector - includes market forecasts to 2010!

The changing corporate face of generics

Sandoz/Hexal, Teva/IVAX, Actavis/Alpharma - who next? On the back of significant growth in both turnover and profits, generic companies are flexing their financial muscle in strategic acquisitions in order to increase market share and defend profit margins.

US market under pressure?

Companies in the world's largest generic market, the US, are feeling the chill wind of competition and price pressure. Against a background of troubling financial results, companies in the US are bracing themselves for tough trading. While new generic opportunities continue to emerge, pressure from drug purchasers to keep prices low, the unknown influence of the Medicare drug benefit in 2006 and the negative impact of shared market exclusivity periods are unsettling the marketplace.

Key company, market and product information

To understand the generic market, The World Generic Markets Report 2006 has been published. Packed with facts, figures and statistics, the 400+ page report provides the most thorough report available on generic markets, products and companies and the issues they face.

Industry consolidation, pressure on prices, biogenerics plus much, much more. This report draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues such as:

--The trend in corporate consolidation

--The trend to greater generic substitution

--Biogenerics: regulatory & technical issues

--US generic pricing pressures

--Key legal challenges

--The political and funding background

--Intellectual property issues

Report Contents

--Global Overview

--Industry consolidation

--The rising influence of India

--Authorised generics

--Biogenerics

--US regulatory reform

--EU/EMEA developments

--Prospects for growth

Country Market Data

--Key facts

--Generic market value & 5-year forecast

--Patent protection/IP

--Pricing/reimbursement

Countries covered:

--Australia Netherlands

--Brazil Russia

--Canada South Africa

--France Spain

--Germany Switzerland

--India United Kingdom

--Italy USA

--Japan

Company Data

--Financial Performance

--ANDAs and launched products

--M&A activity and litigation

Companies covered:

--Alpharma

--Andrx Corporation

--Apotex

--Aspen Pharmacare

--Barr Laboratories

--CIPLA

--Dr Reddy's

--EGIS

--EON Labs

--Hexal AG

--IVAX Corporation

--KRKA

--Lannett

--Lek

--Mayne Pharma

--Merck Generics Mylan Labs

--Perrigo

--Pliva

--Ranbaxy

--ratiopharm

--Gedeon Richter

--Sandoz

--Sawai

--Stada Arzneimittel

--TEVA Pharmaceutical Industries

--Watson Pharmaceuticals

--Winthrop

--Wockhardt

--Zentiva

--Zydus Cadila

For more information visit http://www.researchandmarkets.com/reports/c29061

COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group